An interventional study of transcutaneous auricular neurostimulation (tAN) in Perimenopause and PMDD, sponsored by Texas Christian University. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Texas Christian University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Premenstrual Dysphoric Disorder with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Premenstrual Dysphoric Disorder · United States.
Among the 19 studies in Premenstrual Dysphoric Disorder with a site in United States, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 18th registered.
42 studies on the registry are indexed under Premenstrual Dysphoric Disorder; 10 are open to participants now.
Browse Premenstrual Dysphoric Disorder studies →4 of the 19 studies in Premenstrual Dysphoric Disorder with a site in United States are open now. Recruiting first, the newest first:
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Premenstrual Dysphoric Disorder studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 5
First in 1998; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 50 across 31 interventional studies indexed under Premenstrual Dysphoric Disorder.
Median enrollment 45 across the 15 interventional studies, 50 across the 3 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
Texas Christian University is the lead sponsor of 35 studies on the registry; 7 are open to participants now.
Texas Christian University has 1 study filed under Premenstrual Dysphoric Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Premenstrual Dysphoric Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679074Samphire Group, Inc.CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Premenstrual Dysphoric Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.
The PMS/PMDD study will last four menstrual cycles, for an average of four months in length. The first cycle will be baseline (pre-treatment), the next two cycles will be intervention (treatment), and one final cycle will be follow-up (post-treatment).
The perimenopause study will last three months. The first month will be baseline (pre-treatment), the next month will be intervention (treatment), and the final month will be follow-up (post-treatment).
PMS/PMDD Study:
Inclusion Criteria:
Exclusion Criteria:
Perimenopause Study:
Inclusion Criteria:
Exclusion Criteria:
In both studies we will confirm that participants are symptomatic shortly following enrollment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For perimenopausal women: tAN administration 2 hours daily. For PMS/PMDD women: tAN administration 2 hours daily during the luteal phase.
Device: transcutaneous auricular neurostimulation (tAN)
Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)
Also known as: Sparrow Link
Daily Record of Severity of Problems (DRSP)
The DRSP assesses psychological and physical premenstrual symptoms. This is the primary outcome in the PMS/PMDD study.
Time frame: Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Green Climacteric Scale
The Green Climacteric Scale assesses the degree to which respondents are bothered by a range of different menopausal symptoms. This is the primary outcome in the Perimenopause Study.
Time frame: Participants will complete this measure monthly from study initiation until the end of the study, about three months.
Daily Mood
Each day, participants will be asked to respond to the question "How is your mood today?". Response options range from 1 = extremely bad/negative to 7 = extremely good/positive. This is a secondary outcome in both studies.
Time frame: Participants will fill this out daily from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Daily Hot Flash Frequency
Hot flash frequency will be assessed. This is a secondary outcome in the Perimenopause Study.
Time frame: Participants will respond to questions about hot flash frequency daily from study initiation until the end of the study, about three months.
Daily Hot Flash Severity
Hot flash severity will be assessed. This is a secondary outcome in the Perimenopause Study.
Time frame: Participants will respond to questions about hot flash severity daily from study initiation until the end of the study, about three months.
Daily Sleep Quality
Each day, participants will be asked to respond to the question, "How well did you sleep last night?". Response options range from 1 = Very poor to 5 = Excellent. This is a secondary outcome in the Perimenopause study.
Time frame: Participants will respond to this question daily from study initiation until the end of the study, about three months.
Premenstrual Symptoms Screening Tool (PSST)
The PSST evaluates severity of premenstrual symptoms. This is a secondary outcome in the PMS/PMDD study.
Time frame: Participants will complete this measure each cycle from study initiation until the end of the study, about four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Depression (PHQ-8)
Each cycle participants will complete the Patient Health Questionnaire-8 (PHQ-8) that assesses depression. In both studies this is a secondary outcome.
Time frame: Participants will complete this measure each month/cycle from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Anxiety (GAD-7)
Each cycle/month participants will complete the Generalized Anxiety Disorder-7 (GAD-7) scale that assesses anxiety symptoms. This is a secondary outcome in both studies.
Time frame: Participants will complete this measure each cycle/month from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Insomnia Severity Index (ISI)
Assesses sleep quality and sleep issues. This is a secondary outcome in both studies.
Time frame: Participants will complete the ISI each cycle or monthly from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Positive and Negative Affect Schedule (PANAS)
The PANAS is a self-report measure of a range of positive and negative emotions participants may be experiencing. This is a secondary outcome in both studies.
Time frame: Participants will complete the PANAS each month/cycle from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
Menopause Quality of Life Questionnaire
The Menopause Quality of Life Questionnaire measures how frequently participants have been bothered by a range of different menopausal symptoms. This is a secondary outcome in the Perimenopause Study.
Time frame: Participants will respond to this questionnaire monthly from study initiation until the end of the study, about three months.
Device Usability Questionnaire
Questionnaire designed to assess participants' overall satisfaction with the device and to evaluate how easily they were able to operate it using the provided instructions and support materials. This is a secondary outcome in both studies.
Time frame: This will be administered at the end of the treatment period. Perimenopause study: this will be administered after month 2 (out of 3). PMS/PMDD study: this will be administered after cycle 3 (out of 4). Cycle length varies but is generally 21-35 days.
Plan to share: Yes — Primary and secondary outcomes will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: The investigators will share data at the time of publication. There will be no end date, data will be made available indefinitely.
Access criteria: The investigators will post the deidentified data on open science framework, meaning that it will be publicly available for any researchers who wish to download it.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2028, 17 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Sep 29, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Mar 2028, on Oct 23, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jun 2028, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Premenstrual Dysphoric Disorder →
Texas Christian University